Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Canadian Edition Available
Would you prefer Investing.com's Canadian edition?
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Canaccord Genuity Stick to Their Buy Rating for Seres Therapeutics

May 05, 2021 06:22AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 


Canaccord Genuity analyst John Newman maintained a Buy rating on Seres Therapeutics (NASDAQ:MCRB) on Tuesday, setting a price target of $42, which is approximately 95.53% above the present share price of $21.48.

Newman expects Seres Therapeutics to post earnings per share (EPS) of -$0.19 for the second quarter of 2021.

The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Seres Therapeutics, with an average price target of $38.5.
The analysts price targets range from a high of $46 to a low of $30.

In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $17.56 million and a net profit of -$17.9 million. The company's market cap is $1.97 billion.

According to TipRanks.com, Canaccord Genuity analyst John Newman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.0% and a 43.98% success rate.

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Canaccord Genuity Stick to Their Buy Rating for Seres Therapeutics
 

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
How to stop running the ad blocker on this site Chrome adblock extension AdBlock Plus

We've noticed you're using an ad blocker

We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.

To continue using Investing.com, please allow this domain on your ad blocker.

Allow this domain
Back
Continue with Google
or
Sign up with Email